This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Steady Global Growth, Product Launches Aid Hill-Rom Business
by Zacks Equity Research
Hill-Rom (HRC) holds an encouraging 2022 outlook in terms of product launches.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on the strong Q4 performance in the majority of its segments.
3 MedTech Stocks to Rebound After Coronavirus-Led Recoil
by Sriparna Ghosal
As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.
Here's Why You Should Hold on to Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Omnicell (OMCL) on its strong segmental performance in Q4.
Here's Why You Should Retain Henry Schein (HSIC) Stock Now
by Zacks Equity Research
Investor confidence continues to be high in Henry Schein (HSIC) stock, courtesy of solid prospects.
Intersect ENT Down on Low Propel Sales, Pricing Pressure
by Zacks Equity Research
Intersect ENT (XENT) registers dull Propel performance on poor unit sales in Q4.
Luminex Hits a New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Luminex (LMNX) has been gaining from several recent positive developments.
Here's Why You Should Hold on to Align Technology for Now
by Zacks Equity Research
Investors continue to be optimistic about Align Technology (ALGN) on its strong segmental performance in Q4.
Coronavirus Spreads Rapidly Worldwide: Medtech Stocks in Focus
by Aparajita Dutta
The coronavirus outbreak disrupts manufacturing and supply chain in China, which in turn might have taken a toll on U.S. Medtech stocks.
Fed's Emergency Rate Cut a Boon for These 5 Stocks
by Tirthankar Chakraborty
Fed cuts rates to thwart the coronavirus threat to the economy. After all, worries over how the outbreak will impact corporate profits and the economy have been roiling the U.S. stock market.
Tandem Diabetes Wins FDA's iAGC Designation for Basal-IQ
by Urmimala Biswas
Recent regulatory go-aheads for Tandem Diabetes' (TNDM) insulin pump systems anticipated to boost global pump shipments as well as expand its customer base.
Masimo (MASI) Gets FDA Nod for RRp Monitoring Technology
by Zacks Equity Research
The FDA clearance of this monitoring system is expected to strengthen Masimo's (MASI) portfolio of pulse oximetry technologies.
Here's Why You Should Add Hologic Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on its strong segmental performance in Q1.
CryoLife Wins CE Mark, Boosts Mechanical Valve Foothold in EU
by Zacks Equity Research
CryoLife's (CRY) On-X AAP completes the company's On-Xs heart valve portfolio.
Here's Why You Should Add STERIS (STE) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about STERIS (STE) on its strong segmental performance in Q3.
Medtronic Demonstrates All-Line Growth Despite Cost Concerns
by Zacks Equity Research
Major business lines of Medtronic (MDT) register stellar growth across all customer groups and geographies in Q3.
Here's Why You Should Buy Edwards Lifesciences Stock Now
by Zacks Equity Research
Investor confidence is high in Edwards Lifesciences (EW) stock, courtesy of solid prospects.
Luminex Files for FDA 510(k) Clearance of RSP Flex Assay
by Zacks Equity Research
Once the regulatory clearance comes through, Luminex's (LMNX) Assay portfolio is expected to receive a major boost.
The Zacks Analyst Blog Highlights: Medtronic, PetroChina Company, American Tower, Eversource Energy and Arista Networks
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, PetroChina Company, American Tower, Eversource Energy and Arista Networks
Syneos Health Grows on New Alliances Amid Regulatory Upheavals
by Zacks Equity Research
Syneos Health's (SYNH) new partnerships with AiCure and Indegene Omnipresence seem strategic at the moment.
Here's Why You Should Hold Syneos Health in Your Portfolio Now
by Zacks Equity Research
Syneos Health (SYNH) enjoys high investor confidence on solid prospects.
Integra Launches AmnioExcel Placental Allograft Membrane
by Zacks Equity Research
The launch of this product is expected to boost Integra's (IART) OTT segment.
Orthofix Supports FDA Class III Label Continuation for BGS
by Zacks Equity Research
Orthofix (OFIX) pledges support for the continuation of the FDA's Class III status of BGS devices.
Medical Products Industry Outlook: Growth Prospects Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.
Top Research Reports for Medtronic, PetroChina & American Tower
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Medtronic (MDT), PetroChina Company (PTR) and American Tower (AMT).